The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars
| Autor: | Stig Andersen, Thomas Bo Jensen, Hanne Rolighed Christensen, Dorthe Bartels, Mette Marie Hougaard Christensen, Eva Aggerholm Sædder, Lars Peter Nielsen, Birgitte Klindt Poulsen |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Male
medicine.medical_specialty Denmark medicine.medical_treatment Pharmacology toxicology Anti-TNF drugs 030226 pharmacology & pharmacy Drug Costs Etanercept Danish Biological drugs 03 medical and health sciences Pharmacoeconomics 0302 clinical medicine Cost Savings medicine Humans Pharmacology (medical) 030212 general & internal medicine Intensive care medicine Biosimilar Pharmaceuticals Pharmacology Biosimilars business.industry Biosimilar General Medicine Infliximab language.human_language TNF inhibitor language Female Tumor Necrosis Factor Inhibitors Non-medical shift business medicine.drug |
| Zdroj: | Jensen, T B, Bartels, D, Sædder, E A, Poulsen, B K, Andersen, S E, Christensen, M M H, Nielsen, L & Christensen, H R 2020, ' The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars ', European Journal of Clinical Pharmacology, vol. 76, no. 1, pp. 35–40 . https://doi.org/10.1007/s00228-019-02765-3 Jensen, T B, Bartels, D, Sædder, E A, Poulsen, B K, Andersen, S E, Christensen, M M H, Nielsen, L & Christensen, H R 2020, ' The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars ', European Journal of Clinical Pharmacology, vol. 76, no. 1, pp. 35-40 . https://doi.org/10.1007/s00228-019-02765-3 |
| DOI: | 10.1007/s00228-019-02765-3 |
| Popis: | Purpose A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untappedcost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).Methods We shed light on the considerations and experiences made during the implementation, and present key figures from theimplementation.ResultsThe infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.Conclusion We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars. Purpose A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, butmost countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNFinhibitor biosimilars (infliximab and etanercept).Methods We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.Results The infliximab biosimilar constituted 90.6%of the total amount of infliximab fourmonths following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.Conclusion We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|